Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative design

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504355-28-03

Acronym

NEPA-23-01

Enrollment

Registered

2024-01-10

Start date

2024-03-14

Completion date

2024-09-30

Last updated

2024-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026